How Dymista® is used by patients

Dymista® is a dual-action treatment3 that is clinically proven to relieve the symptoms of moderate to severe allergic rhinitis.4 The two active ingredients (fluticasone propionate/azelastine hydrochloride), combined with the formulation,5 give Dymista® a rapid onset of action and symptom relief for your patients.6

A product that is easy to use, effective, and works quickly is important for maintaining adherence to therapy, and this in turn has a positive effect on clinical outcomes. Therefore, it is important that patients know the correct method for administering Dymista®.

Correct administration technique:5

1Shake the bottle gently for 5 seconds by tilting it upwards and downwards and then remove the protective cap.

2The first time the nasal spray is used, you must prime the pump:

  • Put one finger either side of the spray pump and place your thumb on the bottom of the bottle.
  • Press down and release the pump 6 times until a fine mist appears.
  • Now your pump is primed and ready to use.
  • If the nasal spray has not been used for more than 7 days, you will need to re-prime the pump once by pressing down and releasing the pump.

3Using the spray:

  • After blowing your nose, spray once into each nostril keeping the head tilted downward (see video).
  • The spray tip should be directed to the outside wall of the nose, using the right hand for the left nostril and the left hand for the right nostril.
  • Do not sniff; breathe in gently.
  • After use, wipe the spray tip and replace the protective cap.

Watch the video below for a tutorial:

HOW TO USE DYMISTA®

References

  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856‑889.
  • Scottish Medicine Consortium (SMC). Available at https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
  • Derendorf H, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012; 74(1): 125-133.
  • Klimek L, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy Asthma Proc. 2015; 36(1): 40-47.
  • Dymista® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450. Last accessed: November 2018.
  • Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018; 6(5): 1726-1732.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO

hcp popup title

Mylan Connects is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Mylan Connects today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW